SCYNEXIS (SCYX)
(Delayed Data from NSDQ)
$1.73 USD
-0.03 (-1.70%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $1.72 -0.01 (-0.58%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SCYX 1.73 -0.03(-1.70%)
Will SCYX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SCYX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SCYX
Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?
PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?
SCYX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates
Avalo Therapeutics, Inc. (AVTX) Reports Q2 Loss, Misses Revenue Estimates
Other News for SCYX
Buy Rating Affirmed for SCYNEXIS Amid Antifungal Progress and Market Potential
SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024
Wall Street Analysts Are Bullish on Top Healthcare Picks
Scynexis: Q2 Earnings Snapshot
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update